Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 694

1.
2.
4.

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.

Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.

Clin Cancer Res. 2006 Jan 15;12(2):569-76.

5.

Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.

Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG.

Clin Cancer Res. 2006 Jan 1;12(1):183-90.

6.
7.

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.

J Immunother. 2001 May-Jun;24(3):263-71.

PMID:
11394505
8.

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M.

Blood. 2000 Jun 15;95(12):3900-8.

9.

The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.

Stel AJ, Kroesen BJ, Jacobs S, Groen H, de Leij LF, Kluin-Nelemans HC, Withoff S.

J Immunol. 2004 Nov 15;173(10):6009-16.

10.

Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.

Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, Fan D, Yang M, Han J, Xie Y, Yang C, Zhu Z.

Cancer Lett. 2002 Mar 8;177(1):29-39.

PMID:
11809528
11.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
12.

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S.

BMC Cancer. 2013 Feb 22;13:83. doi: 10.1186/1471-2407-13-83.

13.

Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.

Klein SC, Boer LH, de Weger RA, de Gast GC, Bast EJ.

Scand J Immunol. 1997 Nov;46(5):452-8.

14.

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.

Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG.

J Transl Med. 2014 Jul 9;12:191. doi: 10.1186/1479-5876-12-191.

15.
16.

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22.

17.
18.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

19.

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205. doi: 10.1002/pbc.24237. Epub 2012 Jun 15.

20.

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.

J Immunol. 2000 Nov 15;165(10):5954-61.

Items per page

Supplemental Content

Write to the Help Desk